In a phase 3 randomized trial, investigators evaluated whether finerenone added to the background renin–angiotensin system blockade, thereby reducing albuminuria in adults with type 1 diabetes and chronic...
A nationwide target trial emulation in US veterans with type 2 diabetes found that semaglutide initiation was associated with a twofold increased risk of nonarteritic anterior ischemic optic neuropathy...
In a 4-week naturalistic cohort study using continuous glucose monitoring and ecological momentary assessment, investigators examined whether day-to-day glucose fluctuations are associated with mood...
An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...
A large observational cohort study published in Annals of Internal Medicine examined the effectiveness of statin therapy for primary prevention in adults with type 2 diabetes stratified by predicted 10-year...
A multicenter trial conducted in China found that an artificial intelligence–based insulin clinical decision support system provided glycemic outcomes comparable to standard therapy administered by senior...
The Trump administration announced a new agreement with pharmaceutical companies Eli Lilly and Company and Novo Nordisk to reduce the cost of obesity medication and expand access to these treatments.
As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...
